Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.
NCT ID: NCT03454724
Last Updated: 2019-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
484 participants
INTERVENTIONAL
2020-01-01
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions
NCT05417893
China Resolute Integrity 34/38 mm Study
NCT03118531
A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
NCT04179045
RESOLUTE ONYX China Single Arm Study
NCT03471845
Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
NCT02452736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible subjects shall have up to two de novo lesions in different epicardial vessels ( One lesion in each coronary artery or it's major branch),Target lesion shall have visually estimated diameter stenosis ≥ 70% (or ≥ 50% and has clinical evidence of myocardial ischemia), lesion length ≤ 24mm, reference vascular diameter visually ≥ 2.75mm and ≤ 4.0mm. And subjects must meet all the study inclusion / exclusion criteria before enrolment in the study.
All the subjects shall accept angiography follow up at 12 months post procedure.
OCT subgroup ((N=80, 40 from test group and 40 from control group) shall accept follow up of OCT at immediately and 12 months post procedure. In segment late lumen loss at 12 months post procedure is the primary endpoint, and the percentage of stent strut neointimal coverage assessed with OCT at 12 months post procedure is the key secondary endpoint.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MeRes100 BRS
MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
Xience EES Everolimus Eluting Coronary Stent System
Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
Xience EES
Xience EES is a Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
Xience EES Everolimus Eluting Coronary Stent System
Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
Xience EES Everolimus Eluting Coronary Stent System
Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects with asymptomatic ischemic evidence, stable or unstable angina, or old myocardial infarction \>7 days, suitable for selective PCI. Subjects without contraindications of coronary artery bypass grafting.
3. Subjects be able to understand the purpose of this study, volunteer to participate and sign informed consent, willing to accept invasive imaging follow-up.
1. One de novo target lesion or up-to two de novo target lesions in different epicardial vessels: Different epicardial vessels are defined as left anterior descending artery (LAD) and its branches, left circumflex artery (LCX) arteries and its branches, and right coronary arteries (RCA) and its branches. Thus, for example, the subject must not have two target lesions required to be treated at the LAD and its branches at the same time.
2. Target lesion diameter stenosis ≥ 70% (or ≥ 50% simultaneously shall have clinical evidence of myocardial ischemia), and TIMI flow grade ≥1.
3. Target lesion length ≤ 24mm (estimated visually); reference vessel diameter between ≥ 2.75 mm to ≤ 4.00 mm.
4. Each target lesion can be fully covered by one scaffold.
Exclusion Criteria
3. Subject has undergone prior PCI within the target vessel during the last 12months or plans to receive another PCI within 6months or subject with history of CABG.
4. Subjects with severe heart failure, such as ≥ grade III NYHA or left ventricular ejection fraction \<30% (accessed by ECHO/ultrasound or left ventricular angiography).
5. Blood tests shows the platelet count is less than 100 × 109 / L, or more than 700 ×109 / L, the white blood cells count is less than 3 × 109 / L.
6. Pre-procedure severe liver or kidney functional damaged: serum creatinine\> 1.5mg
/ dl (132.6μmol / L) or subject is receiving hemodialysis, ALT or AST were three times greater than the upper limit of normal.
7. Subjects with bleeding tendency, active gastrointestinal ulcers, history of cerebral hemorrhage or history of subarachnoid hemorrhage, history within six months of ischemic stroke, contraindications of anti-platelet agents and anticoagulants treatment, and subjects cannot receive anti-thrombolytic therapy.
8. Hypersensitive or allergic to antiplatelet drugs(such as aspirin and clopidogrel), anticoagulant drugs(such as heparin), contrast media, and scaffold components(such as PLLA，PDLLA, sirolimus, everolimus, iridium and platinum).
9. The subject's life expectancy is less than 12 months.
10. Subjects who anticipated in other drug or medical device clinical trial but haven't finished the primary endpoint evaluation visit.
11. The investigators judged that subjects were poorly compliance and unable to complete the study as required.
12. Subjects have accepted substantial organ transplant or ready to undergo organ transplant.
13. Subjects have unstable arrhythmia, such as high-risk ventricular premature beats, and ventricular tachycardia.
14. Subjects are receiving or planning to receive chemotherapy.
15. Subjects have received or planning to receive radiotherapy.
16. Subjects with immunosuppressive or autoimmune diseases, are receiving or planning to receive immunosuppressive therapy.
17. Patients suffering from HIV, HBV or HCV infections
18. Subjects are planning to receive or are receiving long-term anticoagulation therapy, such as heparin, warfarin and similar agents.
19. Subjects are planning to accept selective surgery within 12 months, need to discontinue aspirin or clopidogrel (DAPT therapy).
20. Subjects with diffuse peripheral vascular disease, cannot use 6F catheter.
1. Subjects with coronary artery triple vessel lesion in LAD, LCX or RCA, all need to be treated.
2. Target lesion locates in left main.
3. Target lesion locates in the aorto-ostial of RCA (within 3 mm of the origin of the RCA).
4. Target lesion locates within 3 mm of the origin of the LM, LAD and LCX.
5. Target lesion involving a bifurcation with a:
1. Side branch ≥2.0 mm in diameter, or
2. Side branch with diameter stenosis ≥ 50%, or
3. Side branch requiring protection guide wire, or
4. Side branch requiring pre-dilatation.
6. Anatomy proximal to or within the lesion that may impair delivery of the
MeRes100TM or Xience EES, including:
1. Extreme angulation (≥ 90°) proximal to or within the target lesion
2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion
3. Moderate or heavy calcification proximal to or within the target lesion
7. Target lesion involves a myocardial bridge.
8. Target vessel contains thrombus as indicated in the angiographic images or IVUS.
9. Target vessel has been previously treated with a stent at any time prior to the index procedure such that the MeRes100TM or XIENCE stent would need to cross the stent to reach the target lesion..
10. Target vessel has been previously treated with a stent and the target lesion is within 5 mm proximal to a previously treated lesion.
11. Chronic complete occlusive lesion (preoperative TIMI grade 0 flow).
12. Target lesion which prevents complete balloon pre-dilatation, defined as full balloon expansion with the following outcomes:
1. Residual %DS is \< 40% (per visual estimation), ( ≤ 20% is strongly recommended).
2. TIMI Grade-3 flow (per visual estimation).
3. No angiographic complications (e.g., no-reflow, distal embolization, side branch closure).
4. No dissections NHLBI grade D-F.
5. No chest pain lasting \> 5 minutes.
6. No ST depression or elevation lasting \> 5 minutes.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meril Life Sciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gao Runlin, MD
Role: PRINCIPAL_INVESTIGATOR
Fuwai Hospital CAMS
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MeRes-201706
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.